Paulina Kieszkowska-Knapik and Ewa Rutkowska jointly lead the team of ‘top-tier specialists’ at Kieszkowska Rutkowska Kolasinski Kancelaria Prawna sp. j., which assists a lucrative client roster of global pharmaceutical companies, pharmacies, and biotech corporations. The group often assists key clients focusing on AI and medical device development. Kieszkowska-Knapik is well-known for her expertise in reimbursement issues, particularly in relation to orphan drugs and the online sale of medicinal products, while Rutkowska is a key contact for product liability litigation. Michał Tracz is an expert in food and cosmetic products, while Michał Chodorek stands out due to his specialism in medical data use, and the implementation of AI in medical devices and machine learning in healthcare. Key figures within the team include Bartłomiej Sasin, who is noted for his expertise in reimbursement and market access issues, and Justyna Nowak, who is recommended for her strong focus on dietary supplements and clinical trial matters.
Testimonials
Collated independently by Legal 500 research team.
‘Ewa Rutkowska and Katarzyna Kęska deserve attention - both have huge experience. They come with specific solutions, they are open to dialogue. It is a pleasure to work with them. They adapt to the client's needs and have extensive experience and expert knowledge.’
‘A very strong life sciences practice, long experience in the field, client oriented, well-staffed with new talents from the market. They are great for all pharmaceutical law topics, for new technologies and AI, product liability, competition law aspects.’
Key clients
- Celon Pharma S.A.
- Mabion S.A.
Work highlights
- Advised MABION S.A on a major transaction, and concluded an agreement with Novavax Inc., under which Mabion will participate in the production of the Covid-19 (NVX-CoV2373) Novavax vaccine.
- Advised several clients developing AI / ML medical devices on various issues related to the design, development, qualification, and validation of the AI / ML medical device.